Heparin-induced thrombocytopenia: Laboratory diagnosis and management

Annals of Medicine

Volumn 32, Issue SUPPL. 1, 2000, Pages 60-67

  Elalamy, I ^a   Lecrubier, C ^a   Horellou, M H ^a   Conard, J ^a   Samama, M M ^a  

^a HÔTEL DIEU   (France)

Author keywords

Danaparoid; Heparin; Heparin induced thrombocytopenia; Hirudin; Thrombocytopenia; Thrombosis

Indexed keywords

ANTIBODY; DANAPAROID; HEPARIN; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN;

ANAMNESIS; CLINICAL FEATURE; CONFERENCE PAPER; DIAGNOSTIC VALUE; DRUG APPROVAL; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG MARKETING; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; LABORATORY TEST; PRIORITY JOURNAL; SCORING SYSTEM; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA;

ANIMALS; ANTICOAGULANTS; CHONDROITIN SULFATES; DERMATAN SULFATE; DISEASE MODELS, ANIMAL; DRUG COMBINATIONS; FIBRINOLYTIC AGENTS; HEPARIN; HEPARITIN SULFATE; HIRUDIN THERAPY; HIRUDINS; HUMANS; IMMUNOASSAY; PLATELET ACTIVATION; RECOMBINANT PROTEINS; THROMBOCYTOPENIA;

EID: 0034504822     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (43)

1. Heparin-induced thrombocytopenia
2. Clinical presentation of heparin-induced thrombocytopenia
3. Heparin-induced thrombocytopenia: Association of thrombotic complications with heparin-dependent IgG antibody that induces thromboxane synthesis in platelet aggregation
4. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia
5. Fc gamma RIIA H/R 131 polymorphism, subclass-specific IgG anti-heparin/platelet factor 4 antibodies and clinical course in patients with heparin-induced thrombocytopenia and thrombosis
6. Presence of autoantibodies to interleukin-8 or neutrophil-activating peptide-2 in patients with heparin-associated thrombocytopenia
7. Single amino acid mutation of Fc gamma receptor is associated with the development of heparin-induced thrombocytopenia
8. On the role of platelet Fc gamma RIIa phenotype in heparin-induced thrombocytopenia
9. Activation of platelets by sera containing IgG1 heparin-dependent antibodies: An explanation for the predominance of the Fc gammaRIIa 'low responder' (his131) gene in patients with heparin-induced thrombocytopenia
10. Heparin-induced thrombocytopenia - Pathogenesis and treatment
11. Heparin-induced thrombocytopenia: New evidence for the dynamic binding of purified anti-PF4-heparin antibodies to platelets and the resultant platelet activation
12. Antigen generation in heparin-associated thrombocytopenia: The nonimmunologic type and the immunologic type are closely linked in their pathogenesis
13. A mouse model for heparin-induced thrombocytopenia
14. Morphological analysis of microparticle generation in heparin-induced thrombocytopenia
15. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin
16. Immune endothelial-cell injury in heparin-associated thrombocytopenia
17. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: An explanation for the thrombotic complications of heparin-induced thrombocytopenia
18. Plasma P-selectin is increased in thrombotic consumptive platelet disorders
19. Impact of the patient population on the risk for heparin-induced thrombocytopenia
20. Treatment of deep venous thromboses with heparin. Therapeutic management and biological monitoring
21. A fatal low-molecular-weight heparin-associated thrombocytopenia after hip surgery: Possible usefulness of PF4-heparin ELISA test
22. Heparin-induced thrombopenia: Significance and difficulties of precise identification of the immunologic mechanism
23. Heparin-induced thrombocytopenia: A clinico-pathologic syndrome
24. A diagnostic test for heparin-induced thrombocytopenia
25. Laboratory diagnosis of heparin-associated thrombocytopenia and comparison of platelet aggregation test, heparin-induced platelet activation test, and platelet factor 4/heparin enzyme-linked immunosorbent assay
26. Differences in specificity of heparin-dependent antibodies developed in heparin-induced thrombocytopenia and consequences on cross-reactivity with danaparoid sodium
27. Heparin-induced thrombocytopenia in France, 1980-1998
28. Platelet aggregation tests in 26 cases of heparin-induced thrombopenia. Methodological, diagnostic problems and therapeutic aspects
29. Diagnosis and development of heparin-induced thrombocytopenia. Biological and clinical aspects
30. A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia
31. Determination of heparin-induced thrombocytopenia: A rapid flow cytometric assay for direct demonstration of antibody-mediated platelet activation
32. Laboratory tests for the diagnosis of heparin-induced thrombocytopenia
33. New treatment options for heparin-induced thrombocytopenia
34. Persistent heparin induced thrombocytopenia despite therapy with low molecular weight heparin
35. Efficacy and safety of danaparoid sodium (ORG 10172) in critically ill patients with heparin-associated thrombocytopenia
36. Danaparoid in the prevention of thromboembolic complications
37. Heparin-induced thrombocytopenia (HIT): An overview of 230 patients treated with orgaran
38. Heparin-induced thrombocytopenia: Minimising the risks in the elderly patient
39. Heparin-induced thrombocytopenia with thromboembolic complications: Meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range
40. Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: Incidence, effects on aPTT, and clinical relevance
41. Development of argatroban, a direct thrombin inhibitor, and its clinical application
42. Absence of in vitro cross-reaction of pentasaccharide with the plasma heparin-dependent factor of twenty-five patients with heparin-associated thrombocytopenia
43. Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT